Arrowhead Pharmaceuticals (NASDAQ:ARWR) Insider Sells $750,000.00 in Stock

Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) insider James Hamilton sold 10,000 shares of the firm’s stock in a transaction on Thursday, April 23rd. The shares were sold at an average price of $75.00, for a total transaction of $750,000.00. Following the transaction, the insider directly owned 226,958 shares of the company’s stock, valued at $17,021,850. The trade was a 4.22% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available at the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Arrowhead Pharmaceuticals Price Performance

ARWR stock opened at $73.91 on Monday. The company has a fifty day moving average price of $62.83 and a 200-day moving average price of $58.51. The company has a market capitalization of $10.35 billion, a P/E ratio of 48.31 and a beta of 1.26. Arrowhead Pharmaceuticals, Inc. has a 52-week low of $12.44 and a 52-week high of $76.76. The company has a debt-to-equity ratio of 0.29, a quick ratio of 3.38 and a current ratio of 3.38.

Arrowhead Pharmaceuticals (NASDAQ:ARWR) last released its quarterly earnings results on Thursday, February 5th. The biotechnology company reported $0.22 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.60 by ($0.38). The business had revenue of $264.03 million for the quarter, compared to the consensus estimate of $225.66 million. Arrowhead Pharmaceuticals had a net margin of 18.54% and a return on equity of 35.64%. Arrowhead Pharmaceuticals’s revenue was up 10461.3% on a year-over-year basis. During the same period in the previous year, the business posted ($1.39) EPS. As a group, equities analysts expect that Arrowhead Pharmaceuticals, Inc. will post -3.37 EPS for the current year.

Analysts Set New Price Targets

Several equities analysts have recently issued reports on ARWR shares. Piper Sandler reaffirmed an “overweight” rating and set a $110.00 price target (up from $100.00) on shares of Arrowhead Pharmaceuticals in a research note on Tuesday, January 13th. Chardan Capital raised their price target on shares of Arrowhead Pharmaceuticals from $60.00 to $80.00 and gave the company a “buy” rating in a research note on Wednesday, January 7th. Morgan Stanley raised shares of Arrowhead Pharmaceuticals from an “equal weight” rating to an “overweight” rating and raised their price target for the company from $78.00 to $100.00 in a research note on Tuesday, April 21st. B. Riley Financial raised their price target on shares of Arrowhead Pharmaceuticals from $61.00 to $101.00 and gave the company a “buy” rating in a research note on Thursday, January 22nd. Finally, HC Wainwright reaffirmed a “buy” rating and set a $100.00 price target on shares of Arrowhead Pharmaceuticals in a research note on Wednesday, March 25th. One research analyst has rated the stock with a Strong Buy rating, seven have issued a Buy rating and three have assigned a Hold rating to the stock. According to MarketBeat, Arrowhead Pharmaceuticals currently has an average rating of “Moderate Buy” and an average target price of $83.78.

Institutional Investors Weigh In On Arrowhead Pharmaceuticals

A number of large investors have recently bought and sold shares of ARWR. Royal Bank of Canada grew its holdings in Arrowhead Pharmaceuticals by 30.2% in the first quarter. Royal Bank of Canada now owns 45,239 shares of the biotechnology company’s stock worth $576,000 after purchasing an additional 10,496 shares during the period. AQR Capital Management LLC acquired a new stake in Arrowhead Pharmaceuticals in the first quarter worth $514,000. Goldman Sachs Group Inc. grew its holdings in Arrowhead Pharmaceuticals by 34.6% in the first quarter. Goldman Sachs Group Inc. now owns 1,741,666 shares of the biotechnology company’s stock worth $22,189,000 after purchasing an additional 447,456 shares during the period. Empowered Funds LLC grew its holdings in Arrowhead Pharmaceuticals by 6.9% in the first quarter. Empowered Funds LLC now owns 15,252 shares of the biotechnology company’s stock worth $194,000 after purchasing an additional 979 shares during the period. Finally, Focus Partners Wealth grew its holdings in Arrowhead Pharmaceuticals by 1,339.5% in the first quarter. Focus Partners Wealth now owns 16,252 shares of the biotechnology company’s stock worth $207,000 after purchasing an additional 15,123 shares during the period. 62.61% of the stock is currently owned by institutional investors and hedge funds.

Arrowhead Pharmaceuticals Company Profile

Arrowhead Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of RNA interference (RNAi) therapeutics. Since its founding in 2008, Arrowhead has leveraged its proprietary delivery platform—known internally as the Advanced RNAi Compound (ARC) technology—to silence disease-causing genes in patients suffering from genetically defined diseases. The company’s approach aims to offer durable, targeted treatments across a range of therapeutic areas.

The company’s pipeline includes multiple candidates in various stages of development.